Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:FDA
October 2019 |
| gptkbp:atccode |
N02 C
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
hypersensitivity to lasmiditan
|
| gptkbp:dosage_form |
50 mg
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Reyvow
|
| gptkbp:ingredients |
lasmiditan
|
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
dizziness
fatigue nausea somnolence paresthesia |
| gptkbp:structure |
C17 H23 N3 O2 S
|
| gptkbp:used_for |
treatment of migraine
|
| gptkbp:bfsParent |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:bfsLayer |
5
|